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Objective. To study the impact of the neutral endopeptidase (NEP)/neuropeptides (NPs) axis and nuclear factor kappa B (NFκB)
as predictors of prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP). Patients and Methods. 70 patients with
early-stage PC were treated with RP and their tumor samples were evaluated for expression of NEP, endothelin-1 (ET-1) and NFκB
(p65). Time to PSA recurrence was correlated with the examined parameters and combined with preoperative PSA level, Gleason
score, pathological TNM (pT) stage, and surgical margin (SM) assessment. Results and Limitations. Membranous expression of
NEP (P < 0.001), cytoplasmic ET-1 (P = 0.002), and cytoplasmic NFκB (P < 0.001) were correlated with time to PSA relapse. NEP
was associated with ET-1 (P < 0.001) and NFκB (P < 0.001). ET-1 was also correlated with NFκB (P < 0.001). NEP expression
(P = 0.017), pT stage (P = 0.013), and SMs (P = 0.036) were independent predictors of time to PSA recurrence. Conclusions.
There seems to be a clinical model of NEP/NPs and NFκB pathways interconnection, with their constituents following inverse
patterns of expression in accordance with their biological roles and molecular interrelations.
1. Introduction
Neuropeptides (NPs) constitute a family of potent vasocon-
strictor peptides with mitogenic properties relevant to car-
cinogenesis. Endothelin-1 (ET-1) is a major representative,
consistently implicated in prostate cancer (PC) progression
through induction of proliferation of PC cells in vitro, while
in vivo, increased ET-1 levels were detected in plasma and tis-
sue specimens from patients with castrate-resistant PC [1–3].
The enzyme responsible for cleavage and inactivation of
ET-1 and other bioactive NPs is neutral endopeptidase (NEP
or CD10). NEP is a cell surface peptidase normally expressed
by various tissues, including prostate [4, 5] but its loss
of expression has been correlated with tumor progression
to castration resistance by allowing NPs growth-promoting
eﬀects [6].
Nuclear factor kappa B (NFκB) is a transcription factor
known for its prosurvival and antiapoptotic roles in various
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types of neoplasia. The most studied form of NFκB is the
heterodimer formed by the p50 and RelA (p65) proteins.
Emerging preclinical evidence implicates NFκB in growth,
survival, angiogenesis, and metastatic progression of PC cells
[7, 8]. Constitutive activation of NFκB has been detected in
castrate-resistant PC xenografts and in PC tissues [9].
Since the continuously increasing list of prognostic
biomarkers candidate for clinical use in PC and given the
central role played by the NEP/NPs and NFκB pathways
in PC progression, gross data from immunohistochemical
studies of radical prostatectomy (RP) specimens has accu-
mulated. However, the existence of conflicting results as well
as the lack of an integrated investigation of both pathways in
the same study still hampers proper interpretation of data
towards refining the already existing prognostic models of
the disease.
2. Patients and Methods
2.1. Patient Selection. The study enrolled patients over 18
years old with histologically newly diagnosed, early-stage PC,
admitted to the Department of Urology, University Hospital
of Larissa. All patients of the study underwent an open
retropubic radical prostatectomy. Patients were hormone
and treatment (chemotherapy and radiotherapy) naı¨ve at
the time of surgery. No history of previous reproductive or
endocrine diseases was reported. The study was approved
by the Internal Review Board of our institution and written
informed consent was provided by all patients before study
entry.
Patient demographics (age) as well as clinico-patho-
logical parameters, including preoperative PSA level, pT
stage and Gleason score of the primary tumor, lymph node
status, SMs, PSA recurrence, and survival data were recorded.
Hematoxylin and eosin-stained tissue sections from
70RP specimens were examined by a single, blinded
histopathologist, based on the availability of both adequate
followup and representative pathology specimens. The radi-
cal prostatectomy specimens were processed using a whole-
mount technique. Evaluation of histopathological charac-
teristics was made according to recommendations of the
2004World-Health-Organization-(WHO-) sponsored Inter-
national Consultation on Prediction of Patients Outcome
in Prostate Cancer meeting [10]. Cases were divided into 2
Gleason groups: low (≤3 + 4; n = 50) and high (≥4 + 3; n =
20), as there were no lower Gleason score (2, 3, 4) samples
based on the established 3-group histopathological criteria of
current literature (low, medium, and high). Cases were also
grouped according to pT stage into either organ-confined
disease (pT ≤ 2; n = 42) or advanced tumors extending
beyond the prostatic capsule (pT ≥ 3; n = 28). pT3 group
consisted of 11 patients with pT3a disease and 16 patients
of pT3b stage; however due to the small number of patients,
no additional subgroup analysis was performed. With regard
to preoperative PSA levels, patients were categorized in 2
subgroups: <10 ng/mL and ≥10 ng/mL. The majority of
patients had a preoperative PSA level <10 ng/mL (n = 60),
while they also displayed negative SM (n = 49) and lymph
Table 1: Patients’ clinicopathological characteristics (n = 70) and
associations with time to PSA relapse.
Characteristic Subgroup n (%) P
Age (years) ≤65 31 (44.3) 0.277
Range 47–75 >65 39 (55.7)
Pre-op PSA (ng/mL) <10 60 (85.7) 0.143
Range 2.8–23.9 ≥10 10 (14.3)
pT stage
≤2 42 (60.0)
<0.001≥3 28 (40.0)
Gleason score
≤7 (3 + 4) 50 (46.8)
<0.001≥7 (4 + 3) 20 (44.2)
SMs
(−) 49 (70.0)
0.004
(+) 21 (30.0)
LN status
N0 53 (75.7)
0.072N1 6 (8.6)
Nx 11 (15.7)
Pre-op PSA: preoperative PSA; pT stage: pathologic TNM stage; SMs:
surgical margins; LN: lymph node; n: number of patients; P: statistical value.
node status (n = 53). The latter was not included in
most of our statistical analyses due to missing information
regarding a significant number of patients (n = 11 or 15.7%).
Patients’ clinical and pathological characteristics are depicted
in Table 1.
2.2. Immunohistochemical (IHC) Procedures. The RP spec-
imens were fixed in 10% buﬀered formalin solution and
embedded in paraﬃn blocks. Serial sections (4 μm) from
selected 1 or 2 paraﬃn blocks of each case were obtained.
Tissue blocks were chosen based on the presence of both,
the primary and the secondary architectural Gleason pat-
tern of prostate adenocarcinoma, as determined on hema-
toxylin and eosin sections. Sections were deparaﬃnised in
xylene and rehydrated through decreasing alcohols. Antigen
unmasking for NFκB was achieved by treating sections in
a 6mM citrate buﬀer (pH 6) for a total of 20min in a
microwave oven at 850 Watt. Antigen unmasking for NEP
and ET-1 was achieved by boiling sections in Trilogy reagent
(Cell Marque, Rocklin, CA) for a total of 1 hour in a com-
mercially available steamer. After quenching endogenous
peroxidase with 3% hydrogen peroxide solution for 10min,
slides were incubated at room temperature for 30 minutes
with the following primary mouse monoclonal antibodies:
against p65 subunit of NFκB (clone F-6, 1 : 500 dilution,
Santa Cruz Biotechnology, Inc., CA) and anti-NEP (clone
56C6, 1 : 30 dilution, DAKO, Denmark). Adjacent sections
were incubated overnight at 4◦C with mouse monoclonal
antibody against ET-1 (clone TRET-485, 1 : 100 dilution,
SIGMA, UK). Staining was developed with substrate chro-
mogen solution (EnVision, DAKO, Glostrup, Denmark) and
diaminobenzidine for 10minutes. Slides were counterstained
with Harris hematoxylin for 1 minute, dehydrated, and
mounted with DPX solution.
2.3. Assessment of IHC Staining. Assessment of IHC staining
was made according to evaluations in previous studies. NFκB
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immunostaining was cytoplasmic. NEP immunostaining was
membranous and apical cytoplasmic. ET-1 immunostaining
was cytoplasmic. Intensity of immunostaining for all 3
examined parameters was evaluated, using a score from 0 to 3
(0: no staining 1: weak staining, 2: moderate staining, and 3:
strong staining) compared with the background [9, 11, 12].
Weak and moderate staining (0–2) versus strong staining (3)
were considered for statistical analysis of NFκB and ET-1,
classified as low and high expression, respectively [9, 12].
High NEP expression was defined as a score of 2 or greater
(2-3) and low expression as a score of less than 2 (0-1) [11].
The weak ET-1 staining category was assessed to be less
than that of endothelial cells, the moderate ET-1 staining
category was determined to be equal to that of endothelial
cells, and the intense ET-1 staining category exhibited more
than that of endothelial cells. The normal adjacent prostate
gland was used as an internal control marker for the
evaluation of NEP and NFκB expression. IHC reaction was
glandular for all tested parameters (NEP, ET-1, and NFκB).
2.4. Study Endpoints. Our objective was to investigate possi-
ble interrelations between IHC expression of NEP, ET-1, and
NFκB as well as their potential correlations with preoperative
PSA level, Gleason score, pT stage, and SMs in patients with
hormone naı¨ve PC undergoing RP. We further examined the
putative prognostic role of these parameters in association
with time to PSA failure. The response variable, time to PSA
recurrence, was defined as the time fromRP to the time of the
first detectable (nonzero) PSA measurement >0.2 ng/mL.
2.5. Statistical Analysis. The Fisher’s and χ2 tests were used
to explore associations between NEP, ET-1, NFκB expression
and Gleason score, tumor stage, and SM status. Pearson’s
correlation coeﬃcient was reported to determine the correla-
tion between NEP, ET-1, NFκB expression and preoperative
PSA levels. The Kaplan-Meier method was used to determine
the eﬀect of each categorical variable on PSA relapse-free
survival, and the log-rank test was used to compare PSA
relapse-free survival diﬀerences within each variable. For
PSA recurrence-free survival analysis at the univariate and
multivariate level, the Cox proportional hazards model was
used to estimate hazard ratios (HR) with 95% confidence
intervals (CI). Statistical significance was determined by
using two-tailed P values and was reported at P < 0.05
level. Statistical analysis was performed using SPSS (SPSS for
Windows, version 15.0, SPSS, Chicago, IL).
3. Results
Thirty-eight (54%) patients developed PSA recurrence dur-
ing followup and 32 (46%) did not have a PSA relapse. Two
patients (2.8%) expired. The estimated median follow-up
time, as calculated by the reverse Kaplan-Meier method was
30 months (range 12–86) while the median time to PSA
recurrence was 56 months (range 1–74). Among relapsed
patients, 22 received combined androgen blockade (CAB), 1
received local radiotherapy, and 9 patients were treated with a
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Figure 1: Kaplan-Meier plot according to NEP expression for time
to PSA relapse.
combination of CAB and radiotherapy (5 in sequential order
and 4 concurrently).
3.1. NEP Is Associated with Grade, Stage, and Time to PSA
Relapse. According to level of NEP expression, patients were
divided into a group of low (n = 36, 51.4%) and another
of high NEP IHC expression (n = 34, 48.6%). In univariate
analysis, we observed a significant association of NEP with
Gleason score, as the majority of high NEP-expressing
tumors (30/34 or 88.2%) correlated with low Gleason score
(P = 0.003). Similar was the case for the association between
NEP and pT stage, with 25/34 or approximately 73.5% of
tumors with high NEP expression correlating with low pT
stage (P = 0.030) (Table 2).
The expression of NEP was found to be associated with
time to PSA recurrence (r = 0.485), (P < 0.001) (Table 2,
Figure 1). There were no statistically significant correlations
between NEP and preoperative PSA levels (P = 0.076) or
NEP and SMs (P = 0.121) (Table 2).
3.2. ET-1 Is Associated with Grade, Stage, and Time to
PSA Relapse. ET-1 expression was equally divided in two
groups of either low (n = 34, 48.6%) or high (n =
36, 51.4%) immunoreactivity. Elevated ET-1 expression was
correlated with more advanced disease, evidenced by both
pT stage (P = 0.003) and Gleason score (P = 0.008)
in univariate analysis (Table 2). ET-1 was also found to be
an indicator of biochemical progression as its expression
correlated with a smaller time interval from RP until PSA
relapse (r = −0.375), (P < 0.001) (Table 2, Figure 2). There
were no statistically significant correlations between ET-1
and preoperative PSA levels (P = 0.277) or ET-1 and SMs
(P = 0.068) (Table 2).
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Table 2: Correlations between levels of NEP, ET-1, NFκB expression, and clinicopathological characteristics.
Characteristic
NEP
P
ET-1
P
NFκB
Plow high low high low high
n (%) n (%) n (%) n (%) n (%) n (%)
Pre-op PSA
<10 28 (96.6) 34 (82.9)
0.076
32 (94.1) 30 (83.3)
0.277
35 (83.3) 27 (96.4)
0.191≥10 1 (3.4) 7 (17.1) 2 (5.9) 6 (16.7) 7 (16.7) 1 (3.6)
Gleason score
≤7 (3 + 4) 20 (55.6) 30 (88.2)
0.003
19 (55.9) 31 (86.1)
0.008
37 (74) 6 (30)
0.001≥7 (4 + 3) 16 (44.4) 4 (11.8) 15 (44.1) 5 (13.9) 13 (26) 14 (70)
pT stage
≤2 17 (47.2) 25 (73.5)
0.030
14 (41.2) 28 (77.8)
0.003
32 (76.2) 11 (39.3)
0.003≥3 19 (52.8) 9 (26.5) 20 (58.8) 8 (22.2) 10 (23.8) 17 (60.7)
SMs
(−) 22 (61.1) 27 (79.4)
0.121
20 (58.8) 29 (80.6)
0.068
33 (76.7) 16 (59.3)
0.180
(+) 14 (38.9) 7 (20.6) 14 (41.2) 7 (19.4) 10 (23.3) 11 (40.7)
Pre-op PSA: preoperative PSA; pT stage: pathologic TNM stage; SMs: surgical margins; n: number of patients; P: statistical value.
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Figure 2: Kaplan-Meier plot according to ET-1 expression for time
to PSA relapse.
3.3. NFκB Expression Is Correlated with Grade, Stage, and
Time to PSA Relapse. NFκB staining was found to be low in
60% of patients (n = 42) whereas high in 40% of the cohort
(n = 28). There was an association of NFκB expression
with both stage (P = 0.003) and grade (P = 0.002) in
univariate analysis (Table 2). High NFκB expression was also
found to significantly correlate with a shortened time to PSA
recurrence (r = −0.432), (P < 0.001) (Table 2, Figure 3).
There were no statistically significant correlations between
NFκB and preoperative PSA levels (P = 0.191) or NFκB and
SMs (P = 0.180) (Table 2).
3.4. NEP Expression Is Associated with ET-1 and NFκB
Expression. In univariate analysis, a significant correlation
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Figure 3: Kaplan-Meier plot according to NFκB expression for time
to PSA relapse.
Figure 4: Prostate adenocarcinoma Gleason pattern 3. Strong
membranous and apical cytoplasmic IHC staining for NEP (×200).
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Figure 5: Prostate adenocarcinoma Gleason pattern 3. The same area as in Figure 4. (a) Weak-to-moderate cytoplasmic IHC staining for
NFκB (×400); (b) Negative immunoreactivity for ET-1. Positive marker the capillary endothelium (arrows) (×200).
Figure 6: Prostate adenocarcinoma Gleason pattern 3. (a) Strong cytoplasmic IHC staining for NFκB (×200); (b) strong cytoplasmic IHC
staining for ET-1 (×200); (c) strong cytoplasmic IHC staining for ET-1. Positive marker the capillary endothelium (arrow) (×400); (d)
negative immunoreactivity for NEP. Positive marker the normal prostate glands (×200).
was found between IHC expression of NEP and ET-1 (P <
0.001). Same was the case for the NEP-NFκB relationship
(P < 0.001) (Table 3). ET-1 and NFκB expressions were also
interrelated (P < 0.001). IHC expression patterns of NEP,
ET-1, and NFκB are depicted in Figures 4, 5 and 6.
3.5. Other Univariate Correlations. pT stage (P < 0.001),
Gleason score (P < 0.001), and SM status (P = 0.004) were
related with PSA relapse-free survival (Table 1). There was no
statistically significant correlation between age (P = 0.277),
preoperative PSA (P = 0.143) or lymph node status (P =
0.072), and time to PSA recurrence, respectively (Table 1).
Preoperative PSA level was associated with pT stage (P =
0.016) but not with Gleason score (P = 0.123). Stage and
grade were interrelated (P < 0.001).
3.6. NEP, pT Stage and SMs Are Independent Predictors of
Time to PSA Relapse. In multivariate analysis, there was a
significant association between NEP expression and time to
PSA recurrence after controlling for preoperative PSA, tumor
stage, Gleason score, SMs, NFκB, and ET-1 (P = 0.017;
95% [CI] = 0.228 [0.068–0.766]). pT stage (P = 0.013; 95%
[CI] = 3.025 [1.257–7.277] and SM status (P = 0.036; 95%
[CI] = 2.061 [1.049–4.051]) also retained their significance
as predictors of time to PSA recurrence (Table 4).
6 Prostate Cancer
Table 3: Correlations between NEP, ET-1, and NFκB expression.
Variables
NEP
HR [95% CI] PLow High
n (%) n (%)
ET-1
Low 3 31
0.016 [0.003–0.071] <0.001
High 31 5
NFκB
Low 10 33
0.012 [0.001–0.097] <0.001
High 26 1
n: number of patients; HR: hazard ratio; CI: confidence interval; P: statistical
value.
4. Discussion
In this study we have simultaneously examined the expres-
sion of major components of two systems that have sepa-
rately been correlated with PC progression, the NEP/NPs,
and the NFκB pathway.
We have confirmed the previously reported association
between expression of components of the endothelin axis
and stage, grade [11, 13, 14]. We have also observed an
association of ET-1 expression with time to PSA recurrence,
in accordance with results from Rosenblatt et al. [12] who
demonstrated that both the intensity and the combination
product of intensity and extent of ET-1 immunoreactivity
(IRp) but not the staining extent alone predicted biochemical
relapse in a large-scale study of 287 PC specimens from
RP. Recurrence-free survival in patients with strong ET-1
staining was shorter than in those with weaker expression
[12].
Moreover, we have observed that the aggressiveness of
the examined tumors as evidenced by increasing grade
and advanced stage coincided with loss of membranous
NEP, justifying the latter’s biological role in attenuation of
oncogenic signaling induced by NEP substrates. Accordingly,
a significant association was observed between NEP and time
to PSA recurrence.
The prognostic relevance of NEP expression in early
PC is a field of controversies between studies regarding
diﬀerences in localization and level of expression patterns
as well as diﬀerences in correlation or lack thereof with
clinicopathologic parameters, including PSA relapse-free
survival. Loss or decreased expression of NEP was observed
in 219 prostatectomy specimens of patients with PC com-
pared with normal prostate and prostatic intraepithelial
neoplasia (PIN), although no correlation of NEP expression
with clinical parameters (Gleason score and pathologic
stage) or outcome (biochemical recurrence) was observed
in these series [15]. In another series of 223 patients, loss
of membranous NEP expression was significantly associated
with a shorter time to PSA relapse [16]. In contrast, high
NEP expression was associated with higher PSA recurrence
in a cohort of 87 patients [17], in which 34 patients were
lymph node positive and were not included in the recurrence
analysis. The most extensive series investigating NEP as a
predictor of PC reports on 2385 patients treated by RP in a
single institution during a 14-year time period [18]. In these
series, the authors observed a PSA recurrence-free survival
decline from membranous over membrane-cytoplasmic to
exclusively cytoplasmic NEP expression [18]. However, the
best prognosis was observed with NEP negativity, which is
a finding against the results of several preclinical models
[6, 19], including ours [20] and is also at odds with
the results of Osman et al. [16], with the rest of the
results of this same series predicting a worse prognosis
for a nonfunctional localization of NEP as well as the
results of our present study. One could hypothesize that the
mechanism promoting methylation of the NEP promoter
and NEP expression loss inhibits also expression of cancer-
promoting genes with the net eﬀect being an improvement
in prognosis. Alternatively, an artifact of loss of extracellular
NEP during tissue processing in at least part of the samples
remains a possibility. Importantly, staining intensity was not
considered for analysis in their study.
Our findings regarding the clinical usefulness of NFκB
corroborate previous data indicative of association between
NFκB expression and grade [21, 22] and significant improve-
ment of the prediction of outcome with the combination of
Gleason score and nuclear NFκB staining [23]. NFκB has
also been reported as an independent prognostic indicator
of recurrence in groups with positive SMs [24], or lymph
node invasion [25]. A few reports have emphasized on
subcellular NFκB compartmentalization, with reproducible
results regarding the correlation of either cytoplasmic [26],
or nuclear immunoreactivity [27] with PSA failure. In
general, despite diﬀerences in localization between studies,
high NFκB is correlated with inferior outcome.
An issue that has been so far underestimated, despite
its already established preclinical significance, concerns the
potential interrelations between expression of NEP, ET-1,
and NFκB in early PC. In this study we coexamined all three
parameters together at the clinical level and demonstrated
that NEP expression is related to ET-1 and NFκB expression,
with the majority of high NEP-expressing cells demonstrat-
ing a low ET-1 and NFκB expression level and reversely.
In multivariate analysis including preoperative PSA,
tumor stage, grade, SMs, ET-1, and NFκB expression, only
pT stage, SMs, and NEP retained their importance in
predicting PSA recurrence after RP. In fact, the risk of PSA
relapse was approximately 4.386-fold greater in patients with
low NEP expression compared to men with high expression
of membranous NEP. In addition, this risk was greater than
the risk derived from advanced pT stage (3.025 fold) and
positive SM status (2.061 fold). These data confirm that there
is a strong association between NEP expression and PSA
relapse in hormone naı¨ve PC patients and a strong rational
for integration of NEP in the armamentarium of existing
prognostic tools for early prediction of PC recurrence.
Intriguingly, the emergence of significant NEP, ET-1, and
NFκB interrelations (Table 3) illustrates the clinical relevance
of two pathways that might be in close communication.
Our results implicate the existence of two clinicopathological
patterns of hormone naı¨ve PC with regard to the time of
PSA recurrence after RP. The first pattern is featuring high
NEP expression and low ET-1 and NFκB expression and
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Table 4: Multivariate Cox regression analysis.
Variable Groups HR [95% CI] P
NEP low vs high 4.386 [1.305–14.706] 0.017
ET-1 low vs high 0.636 [0.167–2.422] 0.507
NFκB low vs high 0.851 [0.273–2.652] 0.781
pre-op PSA <10 vs ≥10 0.334 [0.101–1.097] 0.071
Gleason score ≤7 (3 + 4) vs ≥7 (4 + 3) 0.637 [0.276–1.473] 0.291
pT stage ≤2 vs ≥3 0.330 [0.137–0.795] 0.013
SMs (−) vs (+) 0.485 [0.247–0.953] 0.036
pT stage: pathologic TNM stage; SMs: surgical margins; pre-op PSA: preoperative PSA; HR: hazard ratio; CI: confidence interval; P: statistical value; vs =
versus.
predicts a prolonged PSA relapse-free survival compared
to the second one, which involves attenuation of NEP
expression accompanied by elevated ET-1 and NFκB levels
and is characterized by a shortened PSA relapse-free survival.
Indeed, at the molecular level, there seems to be a
functional link between the NEP/NPs and NFκB pathways.
NFκB has been suggested as a mediator of the antiapoptotic
actions of NPs, given that prosurvival signaling initiated
by NPs involves activation of the kinases PI3K and Akt,
which then activates NFκB by phosphorylating its inhibitor,
IκB [28, 29]. In a recent in vitro work, we have revealed
an inverse baseline expression pattern of the NEP/NPs
and NFκB/proteasome pathways in androgen-dependent
and androgen-independent PC cells [20]. Further we have
observed that NPs were able to induce NFκB nuclear
translocation and DNA binding, an event that was much
more pronounced in androgen-independent cell lines that
display low levels of NEP. These events were reversed by NP
inhibitors (Patrikidou et al. unpublished data). The current
study is the first linking, at a clinical level, NEP expression
with ET-1 and NFκB expression. These results complement
our in vitro data on PC cell lines.
Nevertheless, several limitations of the present study
should be considered. It should be acknowledged that the
small number of patients included in the present study does
not permit to draw unequivocal conclusions. Further, lowest
Gleason scores (2, 3, and 4) are not represented in the study
population and this might also blunt the validity of our
results, although it might be hypothesized that diﬀerences
between expression of NEP, ET-1, and NFκB might be
even more pronounced based on the underlying biology
of the disease in its earliest phase. The evaluation of SMs,
although clearly defined may be either misinterpreted due to
the presence of crush, thermal, and electrocautery artifacts
[30] or clinically less relevant in locally advanced disease
[31]. Retrospective review of our prospectively collected
data and the relatively short median followup of patients
may have also biased our results. Moreover, the prognostic
values of NEP, ET-1, and NFκB might have been better
established if they had been compared to predicted outcomes
of validated nomograms. Finally, our study was not intended
to be all inclusive of current prognostic markers such as
seminal vesicle involvement, tumormarker ploidy status, and
proliferation indexes.
In conclusion, our study was designed in an eﬀort to oﬀer
an integrated approach of the role of the NEP/endothelin
and NFκB pathways in the clinical course of PC patients. The
relationship between recurrence (given the heterogeneity of
the population), stage and grade of the tumors, and outcome
was an exploratory (hypothesis generating) analysis and the
primary goal of this study was to demonstrate a relationship
between NEP/ET-1 and NFκB signaling. Although further
prospective evaluation to confirm this interaction is required,
the strong preclinical model of PC evolution based on
aberration of both NEP/NPs and NFκB pathways seems to
play a role in the clinical setting. Most importantly, the
significant interrelations that we have suggested to exist
between these two systems, if confirmed in a large prospec-
tive cohort, might encourage not only the incorporation
of their pathological assessment into the current model of
predictive factors but also the concept of their concurrent
pharmacological inhibition to enable a greater therapeutic
benefit in tumors with aggressive biology.
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